A Review of the Impact of Lapatinib on Health-Related Quality of Life in the Management of Advanced Solid Tumors
Julie Price and Quincy Siu-Chung Chu
Department of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Abstract
Lapatinib is an oral dual inhibitor of epidermal growth factor receptor (HER1/ErbB1/EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2) which was approved for use in patients with metastatic breast cancer in 2007. In this review, we discuss the quality of life (QOL) results for patients on clinical trials of lapatinib. Six clinical trials, including 4 phase III and 2 phase II trials, were identified for which QOL outcomes have been reported. The trials generally showed stability of QOL during lapatinib therapy with no trial showing a detrimental effect of lapatinib on QOL. With these results, a discussion of the role of QOL assessments in patients with breast cancer is presented.
Readers of this also read:
- Body Fat Percentages by Dual-energy X-ray Absorptiometry Corresponding to Body Mass Index Cutoffs for Overweight and Obesity in Indian Children
- Coping and Suicidal Ideations in Women with Symptoms of Postpartum Depression
- Protein Modifications as Potential Biomarkers in Breast Cancer
- Exploring the Evolutionary History of the Differentially Expressed Genes between Human Populations: Action of Recent Positive Selection
- Microarray Data Analysis of Gene Expression Evolution
